Table 1. Patient characteristics and neoadjuvant treatments.
| Patient characteristic | Neoadjuvant therapy (n=61) | Upfront resection (n=241) | P |
|---|---|---|---|
| Median age [range], years | 65.9 [45–82] | 68.6 [25–91] | 0.070 |
| Sex (%) | 0.390 | ||
| M | 36 (59.0) | 126 (52.3) | |
| F | 25 (41.0) | 115 (47.7) | |
| Initial resectability (%) | – | ||
| Resectable | 0 | 241 (100.0) | |
| Borderline resectable | 56 (91.8) | 0 | |
| Locally advanced | 5 (8.2) | 0 | |
| Tumor location (%) | 0.254 | ||
| Head | 54 (88.5) | 196 (81.3) | |
| Body/Tail | 7 (11.5) | 45 (18.7) | |
| Clinical T classification (%) | <0.001 | ||
| 1 | 0 | 18 (7.5) | |
| 2 | 0 | 52 (21.6) | |
| 3 | 56 (91.8) | 75 (31.1) | |
| 4 | 5 (8.2) | 0 | |
| X | 0 | 96 (40.0) | |
| Clinical N classification (%) | 0.005 | ||
| 0 | 30 (49.2) | 118 (49.0) | |
| 1 | 31 (50.8) | 50 (20.7) | |
| X | – | 73 (30.3) | |
| Initial CA19-9 [range], U/mL | 169 [1.5–16,600] | 55 [1–22,751] | 0.004 |
| Induction chemotherapy (%) | – | ||
| GTX | 48 (78.7) | – | |
| FOLFIRINOX | 6 (9.8) | – | |
| Gemcitabine/nab-paclitaxel | 1 (1.6) | – | |
| Gemcitabine alone | 2 (3.3) | – | |
| Other | 4 (6.6) | – | |
| Post neoadjuvant therapy CA19-9 (U/mL) | 17 (1.5–3200.0) | – | |
GTX, gemcitabine, docetaxel, capecitabine; FOLFIRINOX, oxaliplatin, irinotecan, fluorouracil, and leucovorin.